These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. McGuire BM; Zupanets IA; Lowe ME; Xiao X; Syplyviy VA; Monteleone J; Gargosky S; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt BF Hepatology; 2010 Jun; 51(6):2077-85. PubMed ID: 20512995 [TBL] [Abstract][Full Text] [Related]
11. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes. Berry SA; Lichter-Konecki U; Diaz GA; McCandless SE; Rhead W; Smith W; Lemons C; Nagamani SC; Coakley DF; Mokhtarani M; Scharschmidt BF; Lee B Mol Genet Metab; 2014 May; 112(1):17-24. PubMed ID: 24630270 [TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients. Diaz GA; Schulze A; Longo N; Rhead W; Feigenbaum A; Wong D; Merritt JL; Berquist W; Gallagher RC; Bartholomew D; McCandless SE; Smith WE; Harding CO; Zori R; Lichter-Konecki U; Vockley J; Canavan C; Vescio T; Holt RJ; Berry SA Mol Genet Metab; 2019 Aug; 127(4):336-345. PubMed ID: 31326288 [TBL] [Abstract][Full Text] [Related]
13. Monitoring the treatment of urea cycle disorders using phenylbutyrate metabolite analyses: Still many lessons to learn. Glinton KE; Minard CG; Liu N; Sun Q; Elsea SH; Burrage LC; Nagamani SCS Mol Genet Metab; 2023 Nov; 140(3):107699. PubMed ID: 37717413 [TBL] [Abstract][Full Text] [Related]
14. Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials. Nagamani SC; Diaz GA; Rhead W; Berry SA; Le Mons C; Lichter-Konecki U; Bartley J; Feigenbaum A; Schulze A; Longo N; Berquist W; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Kronn D; Zori R; Cederbaum S; Merritt JL; Wong D; Coakley DF; Scharschmidt BF; Dickinson K; Marino M; Lee BH; Mokhtarani M Mol Genet Metab; 2015; 116(1-2):29-34. PubMed ID: 26296711 [TBL] [Abstract][Full Text] [Related]
15. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Diaz GA; Krivitzky LS; Mokhtarani M; Rhead W; Bartley J; Feigenbaum A; Longo N; Berquist W; Berry SA; Gallagher R; Lichter-Konecki U; Bartholomew D; Harding CO; Cederbaum S; McCandless SE; Smith W; Vockley G; Bart SA; Korson MS; Kronn D; Zori R; Merritt JL; C S Nagamani S; Mauney J; Lemons C; Dickinson K; Moors TL; Coakley DF; Scharschmidt BF; Lee B Hepatology; 2013 Jun; 57(6):2171-9. PubMed ID: 22961727 [TBL] [Abstract][Full Text] [Related]
16. Quantitation of phenylbutyrate metabolites by UPLC-MS/MS demonstrates inverse correlation of phenylacetate:phenylacetylglutamine ratio with plasma glutamine levels. Jiang Y; Almannai M; Sutton VR; Sun Q; Elsea SH Mol Genet Metab; 2017 Nov; 122(3):39-45. PubMed ID: 28888854 [TBL] [Abstract][Full Text] [Related]
17. Taste-masked formulation of sodium phenylbutyrate (ACER-001) for the treatment of urea cycle disorders. Cederbaum SD; Edwards J; Kellmeyer T; Peters Y; Steiner RD Mol Genet Metab; 2023 Apr; 138(4):107558. PubMed ID: 37004302 [TBL] [Abstract][Full Text] [Related]
18. Glycerol phenylbutyrate (Ravicti) for urea cycle disorders. Med Lett Drugs Ther; 2014 Aug; 56(1449):77-8. PubMed ID: 25118801 [No Abstract] [Full Text] [Related]
19. Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders. Andrade F; Vitoria I; Martín Hernández E; Pintos-Morell G; Correcher P; Puig-Piña R; Quijada-Fraile P; Peña-Quintana L; Marquez AM; Villate O; García Silva MT; de Las Heras J; Ceberio L; Rodrigues E; Almeida Campos T; Yahyaoui R; Blasco J; Vives-Piñera I; Gil D; Del Toro M; Ruiz-Pons M; Cañedo E; Barba Romero MA; García-Jiménez MC; Aldámiz-Echevarría L J Pharm Biomed Anal; 2019 Nov; 176():112798. PubMed ID: 31394303 [TBL] [Abstract][Full Text] [Related]
20. Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrate. Mokhtarani M; Diaz GA; Lichter-Konecki U; Berry SA; Bartley J; McCandless SE; Smith W; Harding C; Le Mons C; Coakley DF; Lee B; Scharschmidt BF Mol Genet Metab Rep; 2015 Dec; 5():12-14. PubMed ID: 28649536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]